Ampsource Pharmaceutical Technology

Ampsource Biopharma Shanghai Inc. (also known as Ampsource Pharmaceutical Technology) is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative long-acting protein and antibody therapeutics. Founded in 2012, the company leverages several proprietary technology platforms, including the HAAG platform for high-affinity antibodies and the PACE platform for super long-acting protein design. Its pipeline focuses on metabolic disorders, autoimmune diseases, and hematology, with lead candidates such as AP025 (an FGF21-Fc fusion protein) and AP026 (a dual FGF21/GLP-1 receptor agonist) targeting NASH and Type 2 Diabetes. In 2022, Ampsource entered into a strategic licensing agreement with Chiatai Tianqing (CTTQ) for the development and commercialization of its metabolic assets in China. The company is also advancing AP017, an anti-TFPI antibody for the treatment of hemophilia, and AP061 for autoimmune indications.